China sxt pharmaceuticals, inc.SXTC.US Overview

SXTC Earnings Table

• When is SXTC's latest earnings report released?

  The most recent financial report for China sxt pharmaceuticals, inc. (SXTC) covers the period of 2024Q4 and was published on 2024/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SXTC's short-term business performance and financial health. For the latest updates on SXTC's earnings releases, visit this page regularly.

• What is the operating profit of SXTC?

  According to the latest financial report, China sxt pharmaceuticals, inc. (SXTC) reported an Operating Profit of 3.42M with an Operating Margin of 691.04% this period, representing a growth of 176.66% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

• How is SXTC's revenue growth?

  In the latest financial report, China sxt pharmaceuticals, inc. (SXTC) announced revenue of 494.46K, with a Year-Over-Year growth rate of -35.23%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

• How much debt does SXTC have?

  As of the end of the reporting period, China sxt pharmaceuticals, inc. (SXTC) had total debt of 983.88K, with a debt ratio of 0.11. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

• How much cash does SXTC have?

  At the end of the period, China sxt pharmaceuticals, inc. (SXTC) held Total Cash and Cash Equivalents of 18.13M, accounting for 0.84 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

• Does SXTC go with three margins increasing?

  In the latest report, China sxt pharmaceuticals, inc. (SXTC) achieved the “three margins increasing” benchmark, with a gross margin of 26.86%%, operating margin of 691.04%%, and net margin of 667.16%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess SXTC's profit trajectory and future growth potential.

• Is SXTC's EPS continuing to grow?

  According to the past four quarterly reports, China sxt pharmaceuticals, inc. (SXTC)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 2.67. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

• What is the FCF of SXTC?

  China sxt pharmaceuticals, inc. (SXTC)'s Free Cash Flow (FCF) for the period is -677.78K, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 424.45% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.